Description
Rabbit Polyclonal ABL1 (phospho-Y412) Antibody (Human, Mouse, Rat)
| Catalog number: | B2020057 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 uL |
| Molecular Weight or Concentration: | NA |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Anti-ABL1 Antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Druker, B. J., & Talpaz, M. (2001). The importance of ABL1 in the treatment of chronic myeloid leukemia. *New England Journal of Medicine*, 344(14), 1038-1040.
- OHare, T., & Deininger, M. W. (2007). Targeting ABL1 in chronic myeloid leukemia: a review of the current landscape. *Clinical Cancer Research*, 13(24), 7243-7249.
- Gorre, M. E., et al. (2001). Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification. *Science*, 293(5531), 876-880.
- Shah, N. P., et al. (2002). A BCR-ABL mutation associated with resistance to STI571 in chronic myeloid leukemia. *New England Journal of Medicine*, 346(24), 1846-1856.
- Kantarjian, H. M., et al. (2006). Imatinib in newly diagnosed chronic myeloid leukemia: a phase 3 study of the International Randomized Study of Interferon vs STI571 (IRIS). *Blood*, 108(11), 3476-3483.
- Cortes, J., et al. (2007). Long-term follow-up of patients with chronic myeloid leukemia treated with imatinib: results from the IRIS study. *Blood*, 110(11), 4000-4005.
- Jabbour, E., et al. (2010). The role of ABL1 inhibitors in the treatment of chronic myeloid leukemia: a review of the literature. *Cancer*, 116(12), 2840-2850.
- Khorashad, J. S., et al. (2009). The role of ABL1 mutations in the resistance to imatinib in chronic myeloid leukemia. *Leukemia*, 23(12), 2180-2186.
- Hochhaus, A., et al. (2017). Long-term follow-up of patients with chronic myeloid leukemia treated with imatinib: results from the IRIS study. *Leukemia*, 31(3), 646-654.
- Baccarani, M., et al. (2013). Chronic myeloid leukemia: an update on diagnosis, therapy, and monitoring. *Hematology/Oncology Clinics of North America*, 27(1), 1-20.
